# Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

> **NCT07226830** · — · NOT_YET_RECRUITING · sponsor: **BioSensics** · enrollment: 25 (estimated)

## Conditions studied

- Myasthenia Gravis Generalized

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07226830
- **Lead sponsor:** BioSensics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226830, "Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07226830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*